The peptide exerts its biological effects by binding to natriuretic peptide receptors, primarily NPR-A, which are transmembrane guanylyl cyclase-coupled receptors expressed in cardiovascular tissues, kidneys, and other target organs. Receptor activation stimulates intracellular guanylyl cyclase activity, leading to increased production of cyclic GMP (cGMP) and activation of cGMP-dependent protein kinases. This signaling cascade results in vasodilation, enhanced renal sodium and water excretion (natriuresis and diuresis), and suppression of the renin-angiotensin-aldosterone system. The peptide's conserved disulfide bond structure is essential for maintaining its bioactive conformation and ensuring high-affinity receptor interaction and downstream physiological responses.

This chicken ANF (1-29) peptide is indicated for research use only in preclinical investigations of cardiovascular and renal physiology, hypertension, heart failure, and fluid-electrolyte homeostasis. It is utilized as a specific agonist in receptor-binding assays, cGMP accumulation studies, and in vitro models of vascular relaxation and renal function. The peptide is also employed in comparative studies across species to understand evolutionary aspects of natriuretic peptide systems and in animal models to evaluate hemodynamic and natriuretic responses. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.

As a research reagent, Atrial Natriuretic Factor (1-29) (chicken) does not have established clinical efficacy for therapeutic use in human patients. This synthetic peptide has not undergone clinical development or received regulatory approval for any medical indication. While natriuretic peptides, including avian variants, have been studied in preclinical models for their cardiovascular and renal effects, the product itself remains an investigational tool for basic and translational research. It has no proven clinical efficacy or safety profile in humans and is strictly intended for laboratory research applications.